Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-019-0398-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Cancer cytopathology
Cancer ResearchOncology
2017English

Consistency Analysis of Programmed Death-Ligand 1 Expression Between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

Journal of Cancer
Oncology
2020English

Quantitative and Pathologist-Read Comparison of the Heterogeneity of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer

Modern Pathology
Forensic MedicinePathology
2016English

Erratum: Erratum: Expression of Programmed Death Ligand-1 on Tumor Cells Varies Pre and Post Chemotherapy in Non-Small Cell Lung Cancer

Scientific Reports
Multidisciplinary
2016English

Prognostic Value of Red Blood Cell Distribution Width in Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death-1 Antibody

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2018English

Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?

Cancer cytopathology
Cancer ResearchOncology
2018English

Prognostic Impact of Serum Transthyretin in Patients With Non‑small Cell Lung Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy